Carin Von Kahr
About Carin Von Kahr
Carin Von Kahr is an Associate Director of MSAT at Asklepios BioPharmaceutical, Inc., with extensive experience in the biopharmaceutical industry, including roles at Amgen, KBI Biopharma, and Biogen.
Current Role at Asklepios BioPharmaceutical
Carin Von Kahr serves as the Associate Director of MSAT at Asklepios BioPharmaceutical, Inc. (AskBio) since 2023. In this role, she is responsible for overseeing the manufacturing science and technology functions within the organization. Her position is based in Durham, North Carolina, where she contributes to the development and optimization of biopharmaceutical processes.
Previous Experience at Biogen
Carin Von Kahr held multiple positions at Biogen, including Senior Manager of Tech Transfer from 2020 to 2022 and Associate Director, Head of Global Tech Transfer from 2022 to 2023. In these roles, she focused on the transfer of technology and processes across global manufacturing sites, ensuring efficient and effective implementation of biopharmaceutical production.
Work History at Amgen
Carin Von Kahr worked at Amgen in various capacities from 2005 to 2014. She began as an Associate Scientist in Cell Culture and later advanced to Senior Engineer. During her tenure, she contributed to the development and optimization of cell culture processes, enhancing the overall efficiency of biopharmaceutical production.
Education and Expertise in Chemical Engineering
Carin Von Kahr earned her Bachelor of Science in Chemical Engineering from North Carolina State University from 1994 to 1998. She furthered her education with a Master of Science in Chemical Engineering from Colorado State University from 1999 to 2001. Her academic background provides a strong foundation for her expertise in biopharmaceutical manufacturing and technology transfer.
Career Development at KBI Biopharma
At KBI Biopharma, Carin Von Kahr served as Associate Director/Director of Manufacturing Sciences from 2015 to 2017. She also held the position of Manager of Manufacturing Sciences from 2014 to 2015. In these roles, she was involved in the development and implementation of manufacturing processes, contributing to the company's biopharmaceutical capabilities.